首页>投融资
Soligenix
增发
Soligenix, Inc.是一家临床阶段生物制药公司,成立于1987年,专注于开发产品,治疗癌症和严重的胃肠道疾病的治疗所产生的危及生命的副作用(仍然是一个未满足的医疗需求),以及开发多种生物防御疫苗和疗法。
基本信息
-
公司全称Soligenix Inc
-
类型
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15人以下
-
地址29 Emmons Drive Suite B-10 Princeton NJ 08540
-
联系电话1-609-5388200
-
邮箱
-
成立时间2011-06-01
投融资
-
2023-05-09增发850万美元未透露
-
2022-11-15上市后再融资120万美元未透露
-
2022-09-06上市后再融资260万美元未透露
-
2022-04-19上市后再融资140万美元未透露
-
2021-06-09上市后再融资86.5万美元未透露
-
2020-12-28上市后再融资150万美元National Institute of Allergy and Infectious Diseases
-
2020-05-07上市后再融资84万美元未透露
-
2017-09-18上市后再融资150万美元National Cancer Institute
-
2017-08-14上市后再融资250万美元未透露
-
2017-08-14未透露250万美元未透露
-
2016-12-14上市未透露未透露
-
2016-12-13上市未透露未透露
-
2016-07-25未透露63.4万美元National Institute of Allergy and Infectious DiseasesBiomedical Advanced Research and Development Authority
-
2015-08-03未透露1000万美元Kodiak Capital Group
-
2014-02-16捐赠/众筹/授予30万美元未透露
-
2013-06-26未透露710万美元Third Security
-
2013-05-03种子轮150万美元未透露
-
2010-07-02未透露590万美元Rockmore CapitalDafna Capital ManagementRosalind Capital PartnersDownsview CapitalIroquois Capital
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国):Veradermics是一家位于美国的生物技术公司,专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台,开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,